Aims/hypothesis Roof plate-specific spondin (R-spondin1; RSPO1) is a modulator of canonical Wg (wingless) plus Int1 (chromosomal integration site of mouse mammary tumour virus on mouse chromosome 15) (cWNT) signalling that induces cWNT target genes. We have demonstrated that Rspo1 is expressed in murine beta cells, and that it stimulates proliferation and insulin secretion, and inhibits cytokine-induced apoptosis, in mouse insulinoma (MIN6) and beta cells. We thus investigated the role of RSPO1 in beta cells in vivo using Rspo1 −/− mice. Methods The effects of Rspo1 deficiency were assessed by determination of cWNT signalling, glucose tolerance and beta cell mass.
enhanced insulin response over 30 min (p<0.05); glucagon responses were normal. Rspo1 deficiency also resulted in a twofold increase in beta cell mass (p<0.05) in association with 2-and 12-fold increases in the number of beta cells positive for antigen identified by monoclonal antibody Ki67 (Ki67) (p<0.01) and insulin-positive ductal cells (p<0.05), respectively. No change in the number of TUNEL-positive beta cells was detected. Islets isolated from Rspo1 −/− animals displayed no differences in glucose-induced insulin secretion or in glucose suppression of glucagon.
Conclusions/interpretation The present study reveals an unexpected role for RSPO1 as a regulator of both beta cell proliferation and neogenesis in vivo, and reinforces the importance of cWNT signalling for the maintenance of normal pancreatic beta cell behaviour. 
Introduction
Type 2 diabetes is a complex metabolic disorder that is increasingly being associated with a loss of functional beta cell mass [1] . Thus, there is a continual growth in the number of studies focused on strategies to maintain and/or promote beta cell growth and function. Interestingly, the canonical Wg (wingless) plus Int1 (chromosomal integration site of mouse mammary tumour virus on mouse chromosome 15) (canonical WNT [cWNT] ) signalling pathway has recently been implicated in the growth as well as the function of beta cells. In most cells of the body, activation of this pathway by WNT-ligand binding to the frizzled (FRZ)/lipoprotein receptor-related protein (LRP) co-receptors results in inhibition of a degradation complex consisting of adenopolyposis coli, glycogen synthase kinase 3 (GSK3)-β and axin, leading to liberation of the transcriptional co-activator, β-catenin [2] . Initial studies identified multiple WNT ligands, FRZ receptors and other modulators of the cWNT signalling pathway in the developing and mature murine pancreas [3] [4] [5] [6] [7] [8] [9] [10] [11] . However, further analyses revealed that the cWNT pathway is also involved in regulating mature beta cell growth. Hence, it has been demonstrated that overproduction of constitutively active β-catenin in the murine beta cell leads to activation of cWNT signalling and a concomitant increase in beta cell proliferation and total mass [12] . In contrast, ectopic production of negative regulators of cWNT signalling, such as AXIN or GSK3-β, decreases beta cell proliferation as well as mass [12, 13] . Moreover, cWNT signalling is also implicated in regulating beta cell function independent of growth. Studies using Lrp5 −/− mice revealed an impairment in glucose tolerance due to reduced glucose-stimulated insulin secretion (GSIS) and this occurred in association with a significant decrease in islet mRNA levels of beta cell transcription factors (e.g. Tcf1 [also known as Vps72], Tcf2 [also known as Hnf1b], Foxa1, Hnf4α [also known as Hnf4a]), glucokinase and insulin-signalling proteins [14] . In line with this observation, incubation of primary mouse islets and INS1 cells in vitro with adipocyte-derived WNT molecules increases insulin secretion and transcription of glucokinase [15] . The roof plate-specific spondin (R-spondin; RSPO) protein family consists of four related members (RSPO1-4) that have structural similarities with conserved cysteinerich furin-like and thrombospondin domains [16] . Numerous studies have demonstrated that RSPO1 is a regulator of the cWNT signalling pathway, both in development [17] [18] [19] and in the adult mouse [17] . Although the precise mechanism by which RSPO1 activates cWNT signalling remains unclear, several recent studies have demonstrated that RSPO family members function as ligands and/or modulators of the FRZ/LRP coreceptors [20, 21] . As a result of these interactions, RSPO induces the cWNT signalling pathway and initiates WNT target gene expression [20] .
We have recently demonstrated the presence of Rspo1 mRNA transcripts in murine pancreas and isolated islets, as well as in the mouse insulinoma (MIN6) and murine beta tumour cell (β-TC) beta cell lines [11] . We have further used these in vitro models to establish that RSPO1 is a beta cell growth factor, stimulating beta cell proliferation and inhibiting beta cell cytokine-induced apoptosis [11] . RSPO1 also enhances insulin secretion in a glucoseindependent fashion in these cells [11] . However, although RSPO1 has been recently demonstrated to play a role in reproductive development [22] , its effects on glucose metabolism in vivo have not been explored. We have therefore now examined whole body glucose homeostasis and markers of beta cell growth and function using the Rspo1 −/− mouse.
Methods

Animals Rspo1
−/− mice were generated by insertion of the LacZ gene followed by a neomycin resistance cassette into exon 3 of Rspo1 and were genotyped as previously described by Chassot et al. [22] . Unless otherwise indicated, animals were given ad libitum access to water and standard rodent chow with a 12 h light/dark cycle. All animal protocols were approved by the Animal Care Committee of the University of Toronto (ON, Canada) and by the Université de NiceSophia Antipolis (France), and all in vivo experiments were performed using mice at both sites (Nice, France and Toronto, Canada). The Rspo1 −/− mice housed in France were on a C57Bl/6 and 129 mixed strain, while the Toronto Rspo1 −/− mice were back-crossed onto a CD1 background.
Preliminary comparison between the two strains showed no differences in body weights, metabolic responses and beta cell mass; therefore, data are shown as combined data from the two colonies. In vitro studies were performed using mice from the Toronto colony only. Wild-type (Rspo1
) and Rspo1 −/− mice were age-(6-12 weeks) and sex-matchedno differences between males and females were detected for any of the variables studied. Immunological and morphometric analyses Mouse pancreas was divided into three portions, and the middle section was weighed, fixed in formalin (Sigma-Aldrich, Oakville, ON, Canada), paraffin-embedded and sectioned. Liver, adipose, muscle and jejunal samples were similarly fixed, sectioned and then stained with haematoxylin and eosin for gross morphometric analysis. For determination of beta cell mass, pancreatic sections were incubated overnight at 4°C with a guinea pig anti-insulin antibody (Dako Diagnostics, Mississauga, ON, Canada). The sections were then incubated for 1 h at room temperature with biotinylated antiguinea pig antibody (Vector Laboratories, Burlington, ON, Canada), and subsequently treated for 1 h with avidinbiotin complex (Vectastain Elite ABC Kit; Vector Laboratories, Burlingame, CA, USA). Slides were stained with 3,3′-diaminobenzidine tetrahydrochloride (Sigma-Aldrich) for 5 min, washed with tap water, and counterstained with haematoxylin. Pancreatic slides were then scanned at the Advanced Optical Microscopy Facility (Princess Margaret Hospital, Toronto, ON, Canada) and beta cell and total pancreatic area per section were measured using Aperio ImageScope software (Aperio Technologies, Vista, CA, USA). Total beta cell mass for each pancreas was determined as the product of the total cross-sectional beta cell area over the total pancreatic area times the weight of the pancreas. Staining for β-catenin was performed as modified from previously described methods [23] . Briefly, pancreatic sections were incubated with mouse anti-β-catenin (BD Biosciences, Mississauga, ON, Canada) followed by immunoperoxidase detection using biotinylated goat antimouse secondary antibody (Vector Laboratories) and streptavidin-horseradish peroxidase (HRP) (Vector Laboratories), with 3,3′-diaminobenzidine tetrahydrochloride (SigmaAldrich) as above. The number of nuclear β-catenin-positive islet cells was counted for each pancreas.
Metabolic tests
Immunoblotting Proteins were collected from pancreatic samples and immunoblotted as previously described by Wong et al. [11] , using primary antibodies targeted against mouse RSPO1 (goat immunoglobulin [Ig]G, 1:1,000; R&D Systems, Minneapolis, MN, USA), or pan-actin (rabbit IgG, 1:1,000; Sigma Aldrich), followed by incubation with HRP-linked anti-goat (1:2,000; Jackson Immunoresearch Laboratories, West Grove, PA, USA) and anti-rabbit (1:2,000; New England Biolabs, Pickering, ON, Canada) secondary antisera and visualisation using electrochemical luminescence (Amersham Pharmacia Biotech, Baie d'Urfe, QC, Canada).
Semi-quantitative real-time-PCR Murine islets were isolated by collagenase digestion and maintained for 2 days, as previously described [11] . Islets were then lysed using the RNeasy Micro Kit, according to the manufacturer's instructions (Qiagen, Mississauga, ON, Canada). Semi-quantitative RT-PCR was performed in a Chromo4 Continuous Fluorescence Detection unit with Opticon Monitor 3 software (BioRad Laboratories, Mississauga, ON, Canada) using Taqman Gene Expression Assays for specific primers (Applied Biosystems, Foster City, CA, USA). All reactions were performed in duplicate, and control reactions were performed without reverse transcriptase enzyme and/or without template. The linearity of amplification of the Taqman primerprobe sets was verified over nine orders of magnitude (data not shown). Ribosomal protein 18S RNA (Hs99999901_sl) was used as the endogenous control for all quantitative analyses of mRNA expression and was not found to change in response to any of the experimental treatments tested (data not shown). Relative quantification of mRNA levels for the cWNT target genes, c-Myc ([also known as Myc] Mm00487803_m1) and cyclin D1 (mM00432359_m1), the beta cell-specific markers, glucokinase (Gck; Mm00439129_m1), Glut2 ([also known as Slc2a2] Mm00446224_m1), insulin 2 (Ins2; Mm00731595_gH), Pdx1 (Mm00435565_m1), and the Rspo isoforms, Rspo1 (Mm00507078_g1), Rspo2 (Mm00555790_m1), Rspo3 (Mm00661105_m1) and Rspo4 (Mm00615419_m1), were calculated using the ΔΔC t method [24] .
In vitro secretion assays Secretion studies using isolated mouse islets were performed as previously described by Li et al. [25] . Briefly, islets were cultured overnight in 20 mmol/l glucose RPMI1640 (Gibco/Invitrogen, Burlington, ON, Canada) with 10% FBS and penicillin/streptomycin. Islets were then washed and incubated with experimental media that consisted of either low (2 mmol/l) or high glucose (20 mmol/l) RPMI 1640 for 2 h. Media samples were centrifuged at 700 g at 4°C for 1 min and the supernatant fraction was collected. Samples were then radioimmunoassayed for insulin and glucagon using insulin and glucagon kits from Linco Research. Islet DNA content was determined by spectrophotometry for normalisation of all data.
Statistical analysis All data are expressed as mean ± SEM. In some experiments, data were log 10 transformed to normalise variance for statistical analysis. Data were analysed by Student's t test or by one-or two-way ANOVA, followed by appropriate post hoc testing using Statistical Analysis System software (SAS v9.1.3, Cary, NC, USA). Statistical significance was assumed at p<0.05.
Results
Rspo1
−/− mice have reduced islet cWNT signalling Rspo1
−/− mice were phenotypically normal, consistent with previously published results [22] . They shared similar body weights to their wild-type counterparts with no differences in their pancreatic weights (Fig. 1a, b) . For exons 4-5 of Rspo1, semi-quantitative real-time-PCR revealed an 82% reduction (p<0.05) in pancreatic transcript levels in Rspo1 −/− knockout mice (Fig. 1c) . To confirm these results, pancreatic lysates from Rspo1 +/+ and Rspo1 −/− animals were also examined by western blot for RSPO1 protein. As shown in Fig. 1d , Rspo1 +/+ pancreatic lysates were positive for RSPO1; the molecular mass of this band was approximately 32 kDa as compared with the expected size of 29 kDa, although it corresponded in migration to a band observed in the positive control, murine small intestine. This RSPO1 immunoreactivity was reduced by 61% in pancreases from Rspo1 −/− mice (p<0.05). Consistent with these findings, mRNA transcript levels for the cWNT target genes c-Myc and cyclin D1 were reduced by 51 and 56%, respectively, in Rspo1 −/− pancreatic lysates (data not shown), while the number of islet nuclear β-catenin-positive cells was decreased by 47% (Fig. 1e, p<0.05) . In contrast, analysis of mRNA levels for the other isoforms of Rspo (Rspo2-4) revealed no Relative expression levels of Rspo1 were normalised to 18S rRNA (n=4-6). d Immunoblotting analysis of RSPO1 from pancreatic lysates. Relative protein levels of RSPO1 were normalised to total actin (n=5-6; representative blot is shown). e Analysis of islet nuclear β-catenin from Rspo1 +/+ and Rspo1 −/− mice. The number of islet nuclear β-catenin-positive cells was normalised to the total number of islet cells per pancreas (n=8). f Semi-quantitative real-time-PCR analysis of Rspo2-4 mRNA in isolated islets of wild-type (white bars) and knockout (black bars) mice. Relative expression levels of Rspo2, -3 and -4 were normalised to 18S rRNA expression (n=4-10). g Haematoxylin and eosin stained sections of adipose, liver, skeletal muscle and jejunal tissues (n=11-12, representative photomicrographs are shown). *p<0.05; ***p<0.001 significant changes in Rspo1 −/− compared with wild-type mice, indicating no compensatory responses (Fig. 1f) . Gross morphological analyses of insulin-responsive tissues from wild-type and knockout mice revealed no remarkable changes in adipose tissue, liver or skeletal muscle (Fig. 1g) . As RSPO1 is known to be a potent gastrointestinal growth factor [7] , we also sought to see if there were changes in the small intestine. Figure 1g demonstrates no notable differences between the jejunal architecture of Rspo1 +/+ and Rspo1 −/− mice.
−/− mice display better glucose handling without changes in insulin sensitivity Fasting glycaemia was in the normal range for wild-type mice (6.3±0.5 mmol/l), and was not significantly different in knockout animals (5.2± 0.5 mmol/l; Fig. 2a ). However, Rspo1 −/− mice had significantly better glycaemic control after an oral glucose challenge (Fig. 2a) . Consistent with this observation, the AUC for the glycaemic response to oral glucose was significantly lower in knockout animals relative to wildtype mice (p<0.05, Fig. 2b ). In contrast, the glycaemic response to an insulin tolerance test (Fig. 2c,d ), and fasting insulin levels (Fig. 2e) were not altered in knockout animals, suggesting normal insulin sensitivity. However, consistent with the improved glycaemic control in Rspo1 −/− mice, there was a significant increase in plasma insulin levels at t=30 min in response to oral glucose in the Rspo1 −/− mice as compared with the muted response observed in the wild-type animals (p<0.05, Fig. 2e ). Plasma glucagon concentrations were not different between the animals in either the fasting state (e.g. at t=0 min) or at t=30 min following the oral glucose challenge (Fig. 2f) .
−/− mice have increased beta cell mass, proliferation and neogenesis One possible mechanism underlying the better glycaemic handling in Rspo1 −/− mice could involve changes in the number of beta cells. Therefore, pancreatic sections were stained for insulin to determine total beta cell mass. Rspo1 −/− mice were found to have significantly increased beta cell mass, by 2.3-fold relative to wild-type controls (p<0.05, Fig. 3a) . To determine the mechanism(s) underlying the changes in beta cell mass, stained sections were first subjected to morphometric analyses. The total number of islets was increased in pancreases from Rspo1 −/− mice (p<0.05; Fig. 3b ), although islet distribution by size (arbitrarily set as 1, 2-100 or greater than 100 beta cells; Fig. 3b ) and average beta cell size (Fig. 3c) were not significantly different between wild-type and knockout animals. However, examination of pancreatic sections that were co-stained for insulin and the proliferative marker, antigen identified by monoclonal antibody Ki67 (Ki67), revealed that proliferation was significantly increased, by 2.3-fold (p<0.01) in knockout mice relative to wild-type animals, mirroring the changes observed in beta cell mass (p<0.01, Fig. 3d ). Examination of beta cell apoptosis, detected by insulin and cleaved-caspase 3 co-staining, demonstrated extremely low levels in all pancreases (∼1-2 apoptotic beta cells per ∼1,500 beta cells), and no differences in beta cell apoptosis could be detected in the Rspo1 −/− mice (data not shown). However, unexpectedly, there were significantly more insulin-positive ductal cells in the knockout mice (by 12-fold, p<0.05), an indication of beta cell neogenesis, whereas such cells were almost completely absent in the Rspo1 +/+ animals (p<0.05, Fig. 3e ). Finally, semi-quantitative real-time-PCR demonstrated that Ins2, Pdx1, Gck and Glut2 mRNA levels were increased in islets isolated from Rspo1 −/− mice compared with those obtained from wild-type animals (p<0.05-0.01, Fig. 3f ).
−/− mouse islets display normal glucose modulation of hormone secretion Basal insulin release under low Fig. 2 Rspo1 −/− mice have improved glycaemic control. a Glycaemic profiles after an OGTT of wild-type (white circles) and knockout (black circles) mice. b AUC of the glucose excursions at 0 to 120 min after administration of an oral glucose load (n=11-12). c Glycaemic responses to an intraperitoneal ITT of wild-type (white circles) and knockout (black circles) mice. d AUC of the glucose excursions at 0 to 120 min after administration of insulin (n=11-12). Levels of plasma insulin (e) (n=17-23) and glucagon (f) (n=6-12) in wild-type (white bars) and knockout (black bars) mice at t=0 and 30 min after administration of an OGTT. *p<0.05 glucose conditions was not statistically different in Rspo1 −/− mice relative to wild-type controls. Furthermore, incubation of islets with high glucose (20 mmol/l) for 2 h stimulated insulin secretion to a similar extent in both groups of animals (p=0.055 in wild-type islets; p<0.05 in knockout islets; Fig. 4a) . Similarly, glucagon secretion under low and high glucose conditions was not different between Rspo1
−/− and wild-type islets (Fig. 4b) .
Discussion
RSPO1 has recently been established as a novel regulator of cWNT signalling in the beta cell [11] . Hence, RSPO1 is produced in murine islets as well as in MIN6 and β-TC beta cells. Furthermore, treatment of MIN6 cells with RSPO1 increases nuclear β-catenin translocation in association with increased c-Myc and Ins2 mRNA transcript levels. Finally, the effects of RSPO1 on MIN6 as well as primary murine beta cells in vitro include enhanced proliferation and protection from cytokine-induced apoptosis, as well as stimulation of insulin secretion [11] . We now provide novel findings that RSPO1 is also a regulator of whole-body glucose homeostasis via changes in beta cell behaviour in vivo. However, unexpectedly and in contrast Fig. 4 Rspo1 −/− islets demonstrate normal glucose modulation of hormone secretion. a, b Effects of low (2 mmol/l) and high (20 mmol/l) glucose on insulin (a) (n=10-13) and glucagon (b) (n=8-13) from isolated islets of Rspo1 +/+ (white bars) and Rspo1 −/− (black bars) mice, as determined by radioimmunoassay. Results were normalised to total DNA content. *p<0.05 . f Semi-quantitative real-time-PCR analysis of Ins2, Pdx1, Gck and Glut2 mRNA in isolated islets from Rspo1 +/+ (white bars) and Rspo1 −/− (black bars) mice (n=4-10). Relative expression levels of each transcript were normalised to 18S rRNA expression. *p<0.05; **p<0.01. BCM, beta cell mass to our in vitro findings, the effects of Rspo1 deficiency in vivo resulted in improved glycaemic tolerance in association with enhanced beta cell mass.
In the present study, we confirmed knockout of Rspo1 in the Rspo1-null mice at the level of DNA by genotyping. Previous analysis of these mice by Southern blot also did not reveal a signal [22] . In contrast, very low levels of Rspo1 mRNA (18% of normal) were detected in islets from the Toronto Rspo1 −/− mice by semi-quantitative real-time PCR for exons 4-5, a finding that has recently been confirmed in the colony in France (10-20% of normal expression levels; unpublished observations). One possible explanation arises from a recent report of two Rspo1 transcripts, such that our primers may have detected the second, 'truncated' Rspo1 transcript (446 bp; transcript ID ENSMUST00000140698). As Rspo1 was knocked out by replacement of a section of exon3 with a LacZ gene and a polyA signal, it is also possible that a hybrid transcript is expressed via production of a read-through message-this would result in a protein without the cysteine-rich domain required for RSPO1 interactions with the FRZ/LRP receptors [16] . Thus, although immunoblotting of pancreatic lysates from Rspo1 −/− mice found detectable but reduced (by 61%) levels of RSPO1 immunoreactivity, these findings are consistent with the marked decreased in cWNT signalling in these animals, as evidenced by a >50% reduction in pancreatic c-Myc and cyclin D1 transcript levels, as well as a 47% decrease in islet nuclear β-catenin localisation. Notwithstanding, further studies are clearly required to fully elucidate the identity of the apparent RSPO1 mRNA transcript and immunoreactivity detected in the Rspo1 −/− mice.
Rspo1 deficiency did not impact overall body and pancreatic weights, and there were no gross morphological differences in three principle insulin-sensitive tissues, namely, adipose tissue, liver and skeletal muscle. Given that RSPO1 is a potent gastrointestinal mitogen [7, 16, 26] , it is interesting to note that there were also no remarkable morphological changes in the small intestine of knockout mice. Together, these findings indicate that, while RSPO1 is essential for normal reproductive system development [22] , it may be dispensable for development of these major nutrient handling tissues.
We have previously shown by RT-PCR that Rspo3 and Rspo4, but not Rspo2, are expressed in murine islets [11] . Here we show by the more sensitive technique of semiquantitative real-time-PCR that all three of these isoforms of Rspo are expressed in murine islets. Nonetheless, although previous studies have shown that many transgenic mouse models demonstrated compensatory responses by upregulating other isoforms of the deficient protein [27] [28] [29] , we were unable to detect any upregulation of Rspo2-4 in islets from Rspo1 −/− mice. This finding suggests that, despite the known similar actions of these four isoproteins in the stimulation of gastrointestinal growth [16] , they do not exhibit compensatory actions in the islet. Somewhat surprisingly, given the stimulatory effect of exogenous RSPO1 on insulin secretion in vitro [11] , the glycaemic profile of Rspo1 −/− mice during an OGTT was found to be significantly reduced relative to Rspo1
animals. This phenomenon was associated with a greater change in plasma insulin from 0 to 30 min in the Rspo1 −/− mice, in the absence of any differences in either the glycaemic response to insulin or fasting insulin levels between Rspo1 +/+ and Rspo1 −/− animals. It is possible that analysis of insulin levels at different time points may reveal further differences between these animals. Nonetheless, these findings suggested that the improved glucose handling in the Rspo1-null mice resided at the level of the pancreatic beta cell. Consistent with this possibility, we found a significant increase in beta cell mass in Rspo1
−/− animals relative to Rspo1 +/+ controls. Notably, this finding was also unexpected given the pro-proliferative and antiapoptotic effects of RSPO1 in the beta cell in vitro [11] . However, such discrepancies in null animal models are not without precedence. For example, although we have previously reported that the incretin hormone glucagonlike peptide-1 enhances beta cell mass in vivo in normal mice and induces beta cell proliferation in vitro, administration of GLP-1 to animals lacking Pi3kγ (also known as Pik3cg) causes a paradoxical reduction in both variables [25] . Similarly, despite the known effect of insulin-like growth factor-1 to enhance beta cell proliferation in vitro, beta cell-specific knockout of the insulin-like growth factor-1 receptor does not alter beta cell mass in vivo [30] . Hence, findings made in vitro must often be re-considered in the light of apparently contradictory effects in the more complex in vivo setting.
To examine the mechanisms underlying the increased beta cell mass in Rspo1 −/− animals in more detail, a variety of factors known to influence the growth of existing beta cells, including proliferation, apoptosis and hypertrophy, were investigated. We found that the increase in beta cell mass occurred in association with an increased number of proliferating beta cells, rather than changes in beta cell apoptosis or beta cell size. However, as the size distribution of the islets was not significantly increased in the knockout animals, these findings suggest that, although significantly increased, the rate of beta cell proliferation was not the major determinant of the increased beta cell mass observed in these mice. Furthermore, the rate of apoptosis in islets from both the wild-type and knockout animals was so low as to effectively preclude a role for this pathway in the regulation of beta cell mass. However, unexpectedly, we did find a profound increase in the number of insulinpositive ductal cells in the Rspo1 −/− mouse pancreas. Such observations have been characterised by others as beta cell neogenesis, whereby ductal cells differentiate to give rise to new beta cells [31] . Although there are no reports of RSPO1 regulating differentiation in adult tissues, previous studies have implicated the cWNT pathway as an inhibitor of differentiation. Hence, inhibition of the cWNT pathway leads to spontaneous adipogenesis, while stimulation of basal cWNT-mediated signalling prevents pre-adipocyte differentiation [32] . Together, these findings suggest that the ductal cells may be a novel target of RSPO1 action in vivo, with Rspo1 deficiency in these cells resulting in enhanced beta cell mass through induction of beta cell neogenesis. However, characterisation of this phenomenon is difficult because of issues related to the identification of ductal beta cell progenitors [33, 34] . Future analyses with ductal-specific markers and/or cell-specific knockout animals will be required to determine the precise contribution of ductal transdifferentiation to beta cell mass in the Rspo1-knockout mouse. Nevertheless, these findings highlight the utility of using global knockout animals to identify novel targets, which would not be possible using either in vitro cell models or cell-specific null animals. The importance of cWNT signalling in the beta cell has recently been highlighted by reports that single nucleotide polymorphisms in the Tcf7l2 gene are strongly associated with risk for development of type 2 diabetes [35] [36] [37] [38] [39] . Interestingly, T cell factor 4 (TCF4), the protein product of Tcf7l2, is a downstream transcription factor that is required for the induction of gene expression by β-catenin [2] . Although it remains unclear to this date how polymorphisms in Tcf7l2 translate to functional defects in beta cells, in vitro expression of dominant negative or small interfering RNA knockdown of Tcf7l2 in beta cells or islets decreases both beta cell proliferation and GSIS [9, 10, 40, 41] , whereas an overproduction of this transcription factor in mouse and human islets protects beta cells from glucotoxicity-and cytokine-induced apoptosis [10] . Hence, an improved understanding of the role of cWNT signalling in beta cell biology will provide insight into the mechanisms underlying type 2 diabetes risk as well as into the pathophysiology of this disease.
In conclusion, our studies using Rspo1 −/− mice have provided insights as to the role of RSPO1 in the beta cell in vivo, and suggest a novel function for this protein as a negative regulator of beta cell neogenesis. Further studies are clearly warranted if RSPO1 is to be considered as a novel target for the therapeutic treatment of patients with type 2 diabetes.
